# US 2026/0027083 A1 · Use of ppar agonist for improvement of energy metabolism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027083 A1
- Document ID: US20260027083A1
- Status: Published application
- Kind: A1
- Application number: 18/996,559
- Filed: 2023-07-19
- Published: 2026-01-29
- Earliest claimed: 2022-07-19
- Assignees: Novmetapharma Co., Ltd.; Postech Research and Business Development Foundation
- Applicants: Novmetapharma Co., Ltd.; Postech Research and Business Development Foundation
- Inventors: Kyong Tai KIM; Eunji OH; Jeonghwa KANG; Sungji CHO; Hoe Yune JUNG; Heon Jong LEE
- Web page: https://patentgrep.com/patent/US20260027083A1

## CPC

- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition for use in preventing or treating metabolic diseases comprising a novel pan-PPAR agonist compound or a salt thereof as an active ingredient. As the pan-PPAR agonist, the compound or the salt thereof may be useful in pharmaceutical compositions for preventing or treating metabolic diseases such as obesity, diabetes, fatty liver diseases, dyslipidemia, cardiovascular diseases, and/or metabolic syndrome, and in food or feed compositions for improving metabolic health.

## Claims

### Claim 1

A method for preventing or treating a metabolic disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following Chemical Formula 1 or a salt thereof as an active ingredient:

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound represented by Chemical Formula 1 or the salt thereof activates PPARα, PPARβ/δ, and PPARγ.

### Claim 3 (depends on 1)

The method of claim 1, wherein the metabolic disease is at least one selected from the group consisting of obesity, diabetes, fatty liver diseases, dyslipidemia, cardiovascular diseases, and metabolic syndrome.

### Claim 4

A method for improving metabolic health in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by Chemical Formula 1 or a salt thereof:

### Claim 5 (depends on 4)

The method of claim 4, wherein the improvement of the metabolic health is at least one effect selected from the group consisting of improvement in obesity, drop in blood sugar, improvement in fatty liver, improvement in lipid metabolism, improvement in blood circulation, and improvement in metabolic syndrome.

### Claim 6

(canceled)
